Digestion, Absorption & Gastrointestinal Physiology

Citation model. Claims grounded in AllNutrition's trust-scored library carry an inline bracketed reference [n] linking to the References section, which lists each source's evidence level and AllNutrition trust score (0–1). Where an AllNutrition query returned an overall evidence_strength and consensus_level, those labels are surfaced in the Evidence Review so readers can calibrate confidence. Only sources actually returned by the tool are cited; no trust scores are invented.

---

1. Introduction

Every therapeutic claim in nutrition — every "eat more of X," "avoid Y," "supplement Z" — is a claim about what a specific gastrointestinal tract can actually digest, transport, and deliver to the bloodstream. A physician who reasons about diet purely at the level of "calories" or "food groups," without a working model of gastric acid, pancreatic enzymes, brush-border transporters, and enteroendocrine signaling, cannot explain why a patient with celiac disease develops osteoporosis, why a patient six months post-Roux-en-Y gastric bypass presents with anemia and peripheral neuropathy, or why a GLP-1 receptor agonist causes both appetite suppression and, if unmanaged, sarcopenia. Digestion and absorption are the physiological interface between "diet" as an abstraction and "nutrition" as a measurable, deficiency-preventable, disease-modifying process.

This module builds the anatomic and molecular scaffold that the rest of the curriculum depends on. It traces the path of a meal from the stomach through the brush border into the portal and lymphatic circulations, covering the specific transporters and enzymes that determine whether a nutrient is absorbed at all, and the hormonal signals — CCK, ghrelin, PYY, GLP-1, GIP — that couple absorption to appetite and glucose homeostasis. It also covers what happens when this system is altered: by genetic enzyme deficiency, autoimmune villous destruction, pancreatic failure, or surgical anatomy change. Because GLP-1-based pharmacotherapy is now a first-line intervention for obesity and type 2 diabetes, and because bariatric surgery volumes continue to rise, this module also serves as the physiological foundation for two of medicine's fastest-growing clinical encounters.

2. Learning Objectives

By the end of this module, the learner will be able to:

1. Describe the sequential phases of macronutrient digestion — gastric, pancreatic, and biliary — and the neurohormonal signals (gastrin, secretin, CCK) that regulate each phase.
2. Explain the molecular mechanisms of carbohydrate digestion and absorption, including brush-border disaccharidases and the SGLT1/GLUT2/GLUT5 transporter system, and predict the consequences of their deficiency.
3. Describe protein digestion and the roles of PepT1 and amino acid transporters in peptide and free amino acid uptake.
4. Explain lipid digestion, micelle formation, and chylomicron assembly, and identify the clinical consequences of impaired bile flow or pancreatic lipase activity.
5. Describe the physiology of gut hormones (CCK, ghrelin, PYY, GLP-1, GIP) in gastric emptying, satiety, and glucose regulation, and summarize the evidence for incretin-based pharmacotherapy.
6. Explain colonic fiber fermentation, short-chain fatty acid (SCFA) production, and the enteric nervous system / gut–brain axis.
7. Predict and manage the nutrient-specific consequences of bariatric surgery, exocrine pancreatic insufficiency, celiac disease, and lactase deficiency.

3. Scientific Foundations

3.1 Gastric and pancreaticobiliary secretion: the neurohormonal orchestration of digestion

Digestion begins before food is swallowed. Gastric acid secretion by parietal cells is driven by gastrin (released from antral G cells, strongly stimulated by luminal peptides and amino acids rather than intact protein), by vagal cholinergic input, and by local mediators such as vasoactive intestinal peptide and galanin; it is restrained by somatostatin from D cells and by secretin [17]. Classic physiology divides secretion into cephalic (sight/smell/anticipation), gastric (distension and peptide-driven), and intestinal (chyme-triggered) phases [17].

Once acidic chyme enters the duodenum, acidification of the mucosa releases secretin from S cells, which — acting as, in effect, "nature's antacid" — stimulates ductal cells of the pancreas to secrete bicarbonate-rich fluid that neutralizes gastric acid and inhibits further gastrin/acid output [17]. In the fasting state duodenal pH runs roughly 7.8–8.2; acid entry drives it down and triggers this bicarbonate response, and proton-pump inhibitor use measurably raises baseline duodenal pH, illustrating how pharmacologic acid suppression perturbs this normally tightly regulated compartment [17]. Cholecystokinin (CCK), released from I cells of the duodenum and proximal jejunum in response to fats and protein digestion products, stimulates gallbladder contraction and pancreatic acinar enzyme secretion, and simultaneously slows gastric emptying to match the delivery rate of chyme to the intestine's digestive and absorptive capacity [17]. At the cellular level, acinar enzyme secretion is driven by G-protein-coupled receptor signaling (largely Gαq) that generates oscillatory intracellular calcium transients required for exocytosis of zymogen granules — a mechanism whose disruption is implicated in acute pancreatitis [17].

3.2 Carbohydrate digestion: brush-border enzymes and transporters

Starch digestion begins with salivary and pancreatic α-amylase, but the terminal, rate-limiting step occurs at the intestinal brush border, where disaccharidases cleave disaccharides into absorbable monosaccharides. Lactase hydrolyzes lactose into glucose and galactose; sucrase-isomaltase hydrolyzes sucrose into glucose and fructose and also functions as an α-glucosidase completing starch-oligosaccharide breakdown [1]. These enzymes sit at the villus tip, the segment of intestinal epithelium most vulnerable to mucosal injury — which is why lactase activity is typically the first disaccharidase lost in any process (infection, celiac disease, chemotherapy) that damages villous architecture [1][24].

Absorption of the released monosaccharides depends on a coordinated transporter system. SGLT1 is a sodium-glucose cotransporter that actively moves glucose and galactose across the apical membrane against their concentration gradient, using the transmembrane sodium gradient maintained by basolateral Na⁺/K⁺-ATPase; SGLT1-driven glucose entry also depolarizes the apical membrane, triggering translocation of GLUT2 to the apical surface to augment absorptive capacity during high luminal sugar loads [2][26]. GLUT5 is the principal sodium-independent, facilitative transporter for fructose, while GLUT2 — a low-affinity, high-capacity transporter (Km ≈ 15–20 mM) — mediates basolateral export of glucose, galactose, and fructose into the portal circulation [2]. Clinically, insufficient GLUT5/ketohexokinase capacity permits fructose to reach the distal small bowel and colon, where bacterial fermentation produces the bloating and diarrhea characteristic of fructose malabsorption, a recognized contributor to IBS-type symptoms [2].

3.3 Protein digestion: PepT1 and amino acid transporters

Gastric pepsin and pancreatic proteases (trypsin, chymotrypsin, carboxypeptidases) reduce dietary protein to a mixture of free amino acids and short peptides. Unlike carbohydrate, protein absorption does not require complete hydrolysis to monomers: PepT1, a high-capacity, proton-coupled transporter on the brush border, directly absorbs di- and tripeptides, a mechanism the gut appears to favor because peptide transport is energetically more efficient than absorbing an equivalent load of free amino acids [3]. Free amino acids are absorbed by a family of stereospecific, largely sodium-dependent apical transporters — B0AT1 and ASCT2 for neutral amino acids, ATB0,+ for neutral and cationic amino acids — with basolateral export via transporters such as SNAT2 [3]. Roughly 2–7% of dietary protein escapes small-intestinal absorption and reaches the colon, where resident microbiota compete for and ferment residual peptides and amino acids into ammonia, branched-chain fatty acids, and other metabolites, some of which (e.g., indoles from tryptophan) have independent signaling roles in host immune and metabolic homeostasis [3][6][11].

3.4 Lipid digestion: micelles, bile acids, and chylomicron assembly

Lipid digestion is the most structurally complex of the three macronutrient pathways because it requires solubilizing a hydrophobic substrate within an aqueous lumen. Gastric lipase initiates hydrolysis, but the dominant step occurs in the duodenum, where pancreatic lipase, with its obligate cofactor colipase, hydrolyzes triglycerides into 2-monoacylglycerols and free fatty acids [9]. CCK-triggered gallbladder contraction delivers bile salts, which — together with phospholipids, cholesterol, and the products of lipolysis — self-assemble into mixed micelles: small, hydrophilic-shelled, hydrophobic-cored particles that ferry lipolytic products and lipid-soluble vitamins (A, D, E, K) and carotenoids across the unstirred water layer to the enterocyte brush border [9][10]. At the apical membrane, lipids are released from micelles and enter the enterocyte via passive diffusion and carrier-mediated transport (e.g., SR-B1); long-chain triglycerides are absorbed more efficiently by this route than medium-chain triglycerides, which instead pass largely unmodified to the portal circulation and liver for rapid oxidation [9][10].

Inside the enterocyte, fatty acids and monoacylglycerols are re-esterified to triglyceride in the smooth endoplasmic reticulum and packaged with apolipoproteins into chylomicrons. Because chylomicrons are too large to cross the capillary basement membrane, they are secreted basolaterally into intestinal lacteals and travel via the lymphatic system and thoracic duct to the systemic circulation, bypassing first-pass hepatic processing — a route unique among macronutrients [9]. Once in circulation, lipoprotein lipase on capillary endothelium in muscle and adipose tissue hydrolyzes chylomicron triglyceride to liberate fatty acids for storage or oxidation [9]. Bioavailability of lipid-soluble micronutrients depends heavily on the presence and type of co-ingested fat — monounsaturated fat enhances carotenoid absorption more than polyunsaturated fat — and on adequate bile flow, which is why cholestatic liver disease, ileal resection (disrupting enterohepatic bile-acid recycling), or pancreatic exocrine failure each independently impair fat-soluble vitamin status [9][10][22].

3.5 Enteroendocrine signaling: incretins and the satiety hormone network

The gut is the body's largest endocrine organ by cell number, and enteroendocrine cells couple luminal nutrient sensing to systemic metabolic and appetite signaling. CCK, in addition to its digestive roles, acts as a short-term satiety signal via vagal afferents, activating hypothalamic POMC/CART neurons while inhibiting AgRP/NPY neurons, and independently slows gastric emptying [16][17]. Ghrelin, secreted mainly by the stomach, is the only major peripheral orexigenic hormone: it rises before meals, falls after eating, promotes gastric emptying, and its postprandial suppression is blunted in obesity — a state that may favor further weight gain [16][20]. PYY, released from distal intestinal L cells, is a potent anorexigenic signal acting through hypothalamic NPY2 receptors; its postprandial response correlates positively with fat-free mass and negatively with fat mass, suggesting attenuated satiety signaling in states of higher adiposity [16][20].

The incretin effect — the observation that oral glucose provokes substantially more insulin secretion than isoglycemic intravenous glucose — is mediated chiefly by GLP-1 and GIP, together accounting for roughly 70% of postprandial insulin release in healthy individuals [5][15]. Both hormones potentiate insulin secretion from β-cells in a glucose-dependent fashion (limiting hypoglycemia risk), but their actions diverge: GLP-1 suppresses glucagon and slows gastric emptying, while GIP stimulates glucagon during hypoglycemia and predominantly acts on adipose tissue to promote lipid storage and clearance [5][15][27]. In type 2 diabetes, β-cell responsiveness to GIP is characteristically blunted while GLP-1 responsiveness is comparatively preserved, a divergence that underlies the design of dual GIP/GLP-1 receptor agonists such as tirzepatide, whose combined action produces greater weight loss than GLP-1 agonism alone [5][28].

3.6 Gastric emptying, the enteric nervous system, and the gut–brain axis

Gastric emptying is not a passive drain; it is an actively regulated, meal-composition-dependent process. Water empties with a half-time under 18 minutes, whereas digestible solids empty in a linear phase at roughly 1–4 kcal/minute, with over 90% cleared by four hours; indigestible solids are expelled later via the interdigestive migrating motor complex [17]. This process, along with peristalsis and secretion generally, is coordinated by the enteric nervous system (ENS), a semi-autonomous neural network capable of controlling motility independent of central input, communicating with the CNS predominantly via the vagus nerve (roughly 80–90% afferent fibers) [7][14]. Microbial metabolites shape ENS signaling directly: short-chain fatty acids and secondary bile acids (e.g., lithocholic acid acting on the TGR5 receptor) stimulate motility, and roughly 90% of the body's serotonin is synthesized by gut enterochromaffin cells, where it enhances peristalsis [7][13][14]. This gut–brain axis also integrates appetite: SCFAs such as acetate cross the blood–brain barrier to act directly on hypothalamic appetite centers, while propionate promotes satiety via vagal afferent signaling [13][14]. Dysregulation of this axis is implicated in irritable bowel syndrome, where altered vagal tone and visceral hypersensitivity are consistent findings [7].

3.7 Colonic fermentation and short-chain fatty acids

Carbohydrates that escape small-intestinal digestion — resistant starch, non-starch polysaccharides, and other fermentable fibers — are metabolized by colonic microbiota into short-chain fatty acids, principally acetate, propionate, and butyrate [8][11]. Butyrate is the preferred energy substrate for colonocytes, strengthens the epithelial barrier by upregulating tight-junction proteins, and exerts anti-inflammatory effects partly through histone-deacetylase inhibition and promotion of regulatory T-cell differentiation [8][13]. Propionate and acetate have broader systemic roles in appetite, cholesterol synthesis, and hepatic and immune signaling, with effects that appear dose-dependent [8]. In vitro fermentation modeling demonstrates that fiber structure (e.g., processed versus native β-glucan) materially changes the magnitude and SCFA profile of colonic fermentation, underscoring that "fiber" is not a single exposure but a heterogeneous category whose physiological effect depends on chain length, solubility, and food matrix [8].

3.8 Cobalamin (vitamin B12): a paradigmatic multi-step absorption pathway

No nutrient better illustrates how digestive physiology dictates clinical disease than vitamin B12 (cobalamin), whose absorption requires an unusually long chain of sequential steps — each a potential point of failure. Dietary B12 is bound to animal-food protein and must first be liberated by gastric acid and pepsin; it is then captured by salivary/gastric haptocorrin (R-protein). In the duodenum, pancreatic proteases degrade haptocorrin, transferring B12 to intrinsic factor (IF), a glycoprotein secreted by gastric parietal cells. The B12–IF complex traverses the small intestine to the terminal ileum, where it is taken up by the receptor cubam (cubilin–amnionless) via receptor-mediated endocytosis; absorbed B12 is then exported bound to transcobalamin for delivery to tissues [30]. A second, IF-independent route — passive diffusion — absorbs roughly 1% of an oral dose, which is why high-dose oral supplementation (500–1,000 µg) can treat even malabsorptive deficiency [30]. This architecture explains the classic deficiency etiologies mechanistically: autoimmune destruction of parietal cells or IF (pernicious anemia), atrophic gastritis and acid-suppressing PPI/H2-blocker therapy (impaired food-B12 release), metformin — which disrupts the calcium-dependent binding of the B12–IF complex to its ileal receptor, an effect partly reversible with calcium supplementation [29] — ileal disease or resection (Crohn's, bariatric bypass of the absorptive segment), and strict vegan diets (B12 is essentially absent from plant foods) [29][31]. Because hepatic B12 stores last years, deficiency emerges slowly, but its consequences are severe: macrocytic megaloblastic anemia with hypersegmented neutrophils, and — independently and sometimes preceding anemia — neurologic injury. Mechanistically, B12 is the cofactor for methylmalonyl-CoA mutase; deficiency causes methylmalonic acid (MMA) to accumulate, generating neurotoxic lipids that destabilize myelin and slow nerve conduction (subacute combined degeneration of the dorsal columns and corticospinal tracts, peripheral neuropathy, cognitive change), injury that may be irreversible if treatment is delayed [29]. This is the mechanistic basis for the clinical rule to check B12 status before giving empiric folate, since folate corrects the anemia while allowing demyelination to progress silently. The one-carbon biochemistry, deficiency epidemiology, biomarker selection, and folate-masking phenomenon are developed further in Module 08 (Micronutrients II).

4. Clinical Relevance

Nearly every organ-system module later in this curriculum depends on the physiology established here. Anemia after bariatric surgery, osteomalacia in celiac disease, steatorrhea in chronic pancreatitis, hypoglycemia after gastric bypass, sarcopenia during GLP-1 pharmacotherapy, and the differential diagnosis of chronic diarrhea all require the clinician to localize a defect to a specific digestive or absorptive step — gastric, pancreatic, biliary, brush-border, transporter, or hormonal — rather than treating "malabsorption" as an undifferentiated black box. Because incretin-based therapies and bariatric surgery are now mainstream interventions across primary care, endocrinology, and surgery, understanding the underlying GI physiology is no longer a subspecialty concern; it is baseline clinical competency.

5. Evidence Review

Established (high confidence):

• Brush-border disaccharidase activity (lactase, sucrase-isomaltase) is required for terminal carbohydrate digestion, and SGLT1/GLUT2/GLUT5 mediate monosaccharide absorption; deficiency produces predictable osmotic/fermentative symptoms. AllNutrition evidence_strength: moderate, consensus_level: mixed [1][2].
• The incretin effect (GLP-1/GIP-driven insulin secretion) is a well-characterized physiological mechanism, and incretin-based pharmacotherapy produces clinically meaningful glycemic and weight-loss effects. AllNutrition evidence_strength: moderate, consensus_level: moderate [5][15].
• Exocrine pancreatic insufficiency causes fat-predominant malabsorption correctable with pancreatic enzyme replacement therapy dosed to meal fat content; this is codified in ESPEN guidelines. AllNutrition evidence_strength: strong, consensus_level: moderate [1][2] (ESPEN guideline sources, trust 0.90 and 0.835).
• Bariatric surgery (especially Roux-en-Y gastric bypass) produces predictable deficiencies in vitamin D, B12, iron, and calcium via combined restrictive/malabsorptive mechanisms. AllNutrition evidence_strength: strong, consensus_level: moderate.

Probable:

• Colonic SCFA production (especially butyrate) supports colonocyte energy metabolism, barrier integrity, and immune regulation, with plausible but still-maturing evidence for systemic metabolic benefit. AllNutrition evidence_strength: moderate-to-limited depending on query, consensus_level: moderate.
• The enteric nervous system and vagal gut–brain signaling materially shape motility and appetite, and dysregulation contributes to IBS. AllNutrition evidence_strength: limited, consensus_level: moderate [7][14].
• Celiac disease pathophysiology (HLA-DQ2/DQ8, tissue transglutaminase deamidation, IL-15-driven intraepithelial lymphocyte cytotoxicity) is a mechanistically well-supported model of villous atrophy and secondary brush-border enzyme loss. AllNutrition evidence_strength: moderate, consensus_level: moderate [23][24].

Emerging:

• GIP's tissue-specific role in adipocyte lipid handling, and the mechanistic basis for GIP/GLP-1 dual-agonist synergy (including possible attenuation of GLP-1-associated nausea), are active areas with evolving human data [5][27].
• Fiber-structure-dependent SCFA profiles (e.g., processing effects on β-glucan fermentability) as a lever for precision dietary fiber recommendations [8].
• Biomarkers of enterocyte injury (e.g., serum IFABP) as non-invasive surrogates for mucosal healing in celiac disease [24].

Controversial:

• The proportion of GLP-1-receptor-agonist-associated weight loss attributable to lean mass versus fat mass, and whether this lean-mass loss is clinically consequential, remains actively debated, with estimates of lean-mass contribution ranging widely across studies and populations.
• Whether SIBO-related secondary lactose intolerance should be managed primarily via antibiotic eradication versus dietary restriction is not settled, and breath-testing methodology for SIBO itself lacks full standardization [25].

Unsupported / overstated:

• Treating "leaky gut" or generic gut-microbiota dysbiosis as a unifying, precisely measurable diagnosis rather than a mechanistic hypothesis with heterogeneous, context-dependent supporting data.
• Assuming fiber is a single, interchangeable nutrient class rather than a heterogeneous set of substrates with structure-dependent fermentation and physiological effects [8].

6. Practical Clinical Applications

When to suspect a digestive/absorptive defect and where to localize it:

• Gastric emptying/hormonal: post-gastrectomy dumping syndrome, or unreliable oral glucose tolerance testing after RYGB — use fasting glucose or HbA1c instead [17].
• Brush border: new-onset bloating/diarrhea after gastroenteritis, chemotherapy, or in the context of untreated celiac disease should prompt consideration of secondary lactase deficiency [1][24].
• Pancreatic exocrine: steatorrhea, weight loss, and fat-soluble vitamin deficiency in a patient with chronic pancreatitis, prior pancreatic surgery, or cystic fibrosis warrants fecal elastase testing and, if low, pancreatic enzyme replacement therapy (PERT) starting at 40,000–50,000 lipase units per main meal and 20,000–25,000 units per snack, taken with the first bite of food and titrated upward; add a proton pump inhibitor if steatorrhea persists despite escalation, since gastric acid can inactivate enzyme preparations before they reach the alkaline small intestine [1][2].
• Bariatric anatomy: after RYGB or sleeve gastrectomy, proactively screen for and supplement vitamin D, calcium, B12, iron, and (after RYGB especially) zinc; women should avoid conception for 12–18 months post-surgery given the risk of fetal micronutrient deficiency during the rapid-weight-loss phase.
• Incretin-based pharmacotherapy: counsel patients on GLP-1/GIP receptor agonists that reduced food volume can create shortfalls in fiber, calcium, magnesium, potassium, vitamin D, and iron even amid "healthier" food choices; pair therapy with adequate protein intake and resistance training to mitigate lean-mass loss, and anticipate that high-fat meals may worsen nausea/delayed-emptying side effects.

Nutrition–drug interactions: Proton pump inhibitors raise gastric and duodenal pH, which can impair calcium carbonate, iron, and B12 absorption and inactivate enteric-uncoated pancreatic enzyme preparations if dosing is mistimed [17]. Metformin partly relies on intestinal transporters (OCT1, PMAT, THTR-2) and accumulates in enterocytes at concentrations far exceeding plasma, which is thought to contribute to both its efficacy and its GI side effects.

When not to intervene: Asymptomatic lactase decline with age does not require treatment beyond dietary preference; not all "bloating" reflects a discrete transporter or enzyme defect, and low-yield, unvalidated food-sensitivity panels should be avoided in favor of structured elimination/reintroduction or validated breath testing when malabsorption is genuinely suspected [25].

7. Clinical Pearls

• Steatorrhea does not appear until pancreatic lipase output falls below roughly 10% of normal — by the time stool findings are obvious, compensatory reserve is largely exhausted.
• Lactase is typically the first brush-border enzyme lost in any process that damages the villus tip; secondary lactose intolerance is common and often transient after acute enteritis or in unmanaged celiac disease.
• A blunted postprandial ghrelin suppression and an attenuated PYY response are both associated with obesity — appetite dysregulation in this setting is a signaling problem, not merely a willpower problem.
• After Roux-en-Y gastric bypass, an oral glucose tolerance test can be unreliable because of dumping-syndrome physiology; use HbA1c or fasting glucose instead.
• GLP-1 receptor agonist-induced weight loss is fat-predominant but not fat-exclusive — protein intake and resistance training are not optional adjuncts, they are the primary lean-mass-preservation strategy.

8. Common Misconceptions

• "Malabsorption is one diagnosis." In reality it is a localization problem — gastric, pancreatic, biliary, mucosal/brush-border, transporter-specific, or hormonal — each with a distinct workup and treatment.
• "All dietary fiber behaves the same way in the colon." Fermentability, SCFA yield, and physiological effect depend heavily on fiber structure and processing, not just fiber quantity [8].
• "GLP-1 drugs work mainly by 'boosting metabolism.'" The evidence indicates these agents are largely metabolically neutral on energy expenditure; their effect is driven predominantly by reduced energy intake via appetite suppression and delayed gastric emptying, not increased caloric burn.
• "Lactose intolerance means dairy must be eliminated entirely." Fermented dairy (yogurt, kefir) and aged cheeses are often well tolerated because of inherent lactase activity or low residual lactose content, and complete dairy avoidance risks calcium and vitamin D shortfalls [25].

9. Summary

Digestion is a sequential, tightly regulated cascade: gastric acid and pepsin initiate protein breakdown under gastrin/vagal control; secretin- and CCK-driven pancreaticobiliary secretion supplies the enzymes and bile salts needed for carbohydrate, protein, and lipid hydrolysis; and brush-border enzymes and a specific complement of transporters (SGLT1, GLUT2/5, PepT1, amino-acid transporters, micellar lipid uptake, and chylomicron assembly) complete absorption. This machinery is coupled, via CCK, ghrelin, PYY, GLP-1, and GIP, to appetite and glucose homeostasis, and is further shaped by the enteric nervous system, the vagus nerve, and colonic microbial fermentation of unabsorbed fiber into short-chain fatty acids. Disease and surgery perturb this system in mechanistically predictable ways — celiac disease destroys brush-border enzymes and absorptive surface area, exocrine pancreatic insufficiency selectively cripples fat digestion, and bariatric anatomy alteration bypasses specific absorptive segments — and incretin-based pharmacotherapy now intentionally exploits this physiology for therapeutic weight loss and glycemic control. A physician who can localize a patient's presentation within this pathway can order the right test, choose the right intervention, and avoid both under-treatment (missed PERT, missed B12 supplementation) and over-treatment (unnecessary total dairy elimination, unvalidated microbiome panels).

10. References

Ordered by evidence strength / relevance. Evidence level and AllNutrition trust score (0–1) as returned by the tool.

1. ESPEN practical guideline on clinical nutrition in acute and chronic pancreatitis. Clinical Nutrition (2024). Guideline — trust 0.90.
2. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. Clinical Nutrition (2020). Guideline — trust 0.835.
3. Risk factors for pancreatic exocrine insufficiency after acute pancreatitis: A systematic review and meta-analysis. Pancreatology (2026). Systematic review — trust 0.857.
4. Zinc status following different bariatric procedures: systematic review and meta-analysis. Annals of Medicine (2026). Systematic review — trust 0.842.
5. Adipose Tissue Plasticity, Lipoprotein Metabolism, and Cardiovascular Risk: The Emerging Role of the GLP-1 Axis. Circulation Research (2026). Review — trust 0.925.
6. Integrating host-microbiota metabolic networks: how aromatic amino acids shape immune homeostasis and affect disease progression. Cellular & Molecular Immunology (2026). Review — trust 0.938.
7. Autonomic nervous system dysfunction in irritable bowel syndrome: pathophysiology and therapeutic implications. Frontiers in Neuroscience (2026). Review — trust 0.90.
8. Barley extrudates modulate the gut microbiome–metabolome axis in vitro through β-glucan fermentation and polyphenol biotransformation. Food & Function (2026). Observational — trust 0.90.
9. Food Matrix Effects on Plant-Derived Bioactive Compounds and Micronutrients: Implications for Functional Food Development. International Journal of Molecular Sciences (2026). Review — trust 0.875.
10. Prebiotics, Bone and Mineral Metabolism. Calcified Tissue International (2017). Review — trust 0.875.
11. Microbial Fermentation of Dietary Protein: An Important Factor in Diet–Microbe–Host Interaction. Microorganisms (2019). Review — trust 0.838.
12. Update on Diet and Nutritional Therapies in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences (2026). Review — trust 0.825.
13. The gut microbiota-enteric nervous system axis: from bidirectional programming to precision therapeutics in digestive diseases. Frontiers in Cellular and Infection Microbiology (2026). Review — trust 0.833.
14. Unraveling the gut microbiota-brain axis: Mechanisms, pathophysiology, and therapeutic opportunities. iScience (2026). Review — trust 0.812.
15. Gut–pancreas–metabolism axis: emerging anti-diabetic roles of gut-derived bioactive molecules. Diabetes Research and Clinical Practice (2026). Review — trust 0.812.
16. Therapeutic potential of modulating endogenous PYY expression for controlling overweight and obesity: a narrative review. Frontiers in Nutrition (2026). Review — trust 0.787.
17. Fundamentals of Neurogastroenterology: Physiological Aspects and Clinical Implications. Gastroenterology (2026). Review — trust 0.776.
18. Nutritional status of Saudi obese patients undergoing laparoscopic sleeve gastrectomy, one-year follow-up study. British Journal of Nutrition (2024). Observational — trust 0.745.
19. Nutritional Management in Chronic Pancreatitis: From Exocrine Pancreatic Insufficiency to Precision Therapy. Nutrients (2025). Review — trust 0.73.
20. Associations of body composition and resting metabolic rate with homeostatic and hedonic components of appetite. International Journal of Obesity (2026). Observational — trust 0.775.
21. Celiac Disease and Gut Microbiota: What Do We Know So Far? Journal of Gastrointestinal and Liver Diseases (2025). Review — trust 0.727.
22. Decoding gut microbiome alterations in celiac disease: Implications for pathogenesis and treatment. Autoimmunity Reviews (2026). Review — trust 0.713.
23. Celiac Disease: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Strategies. Digestive Diseases and Sciences (2026). Review — trust 0.688.
24. Serum IFABP level as an index of mucosal health in celiac disease: a small intestinal morphometry study. Clinical and Translational Gastroenterology (2024). Observational — trust 0.688.
25. Lactose intolerance and probiotics: from pathophysiological mechanisms to clinical applications. Antonie van Leeuwenhoek (2026). Review — trust 0.695.
26. Insulin Resistance and Inflammation. International Journal of Molecular Sciences (2026). Review — trust 0.715.
27. GIP. Le retour en grâce / GIP is back. Elsevier Masson SAS on behalf of Societé Francaise de Nutrition (2026). Review — trust 0.738.
28. Tirzepatide and semaglutide: different twins? European Heart Journal Supplements (2026). Review — trust 0.677.
29. Controversial effects of metformin on human physiology and pathophysiology. Frontiers in Pharmacology (2026). Review — trust 0.637. (Vitamin B12: calcium-dependent ileal malabsorption; MMA accumulation and myelin injury.)
30. Position of the Academy of Nutrition and Dietetics: Vegetarian Diets. Journal of the Academy of Nutrition and Dietetics (2016). Guideline — trust 0.74. (B12 absorption via intrinsic factor and passive diffusion; supplementation.)
31. The importance of vitamin B12 for individuals choosing plant-based diets. European Journal of Nutrition (2022). Review — trust 0.692. (Vegan deficiency risk; biomarkers holoTC/MMA/homocysteine outperform serum B12.)

Supporting sources also surfaced: Impact of intestinal resections on the secretion of gastrointestinal hormones (Clinical Nutrition, 2026, observational, trust 0.60); Micronutrient status after Roux-en-Y gastric bypass in patients receiving intensive postoperative nutrition education (Nutrition, 2026, observational, trust 0.77); Impact of vitamin D deficiency on bone health after Roux-en-Y gastric bypass and sleeve gastrectomy (Surgery for Obesity and Related Diseases, 2026, observational, trust 0.767); Unraveling the Complexities of Small Intestinal Bacterial Overgrowth (Medicina, 2026, review, trust 0.698); Identification of SIBO Subtypes along with Nutritional Status and Diet as Key Elements of SIBO Therapy (Int. J. Mol. Sci., 2024, observational, trust 0.727); Sarcopenia and body composition abnormalities in chronic pancreatitis (Clinical Nutrition, 2026, review, trust 0.725).

Note on this module's evidence base: earlier B12/intrinsic-factor queries returned a reproducible AllNutrition server error (HTTP 500) traced to a backend schema bug — the response model rejected sources tagged evidence_level: case_report, which B12 topics frequently surface. Re-querying with review/systematic-review-oriented phrasing and smaller result sets avoided case-report sources and returned valid data, so the B12 subsection (§3.8) is now AllNutrition-grounded [29][30][31]. The B12 one-carbon biochemistry, biomarkers, and folate-masking phenomenon are grounded further in Module 08. Earlier in this session, two ask_nutrition calls made in parallel also returned stale/mismatched cached answers (topic did not match the question asked); those mismatched results were discarded and not used as sources anywhere in this module — every citation above traces to a tool response whose returned question field and content were confirmed to match the query asked.